SCOPUS 정보 검색 플랫폼

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 17, 2001, Pages 9-18

Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias

(2) Kantarjian, Hagop M a Talpaz, Moshe a

a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYTARABINE; HYDROXYUREA; IMATINIB; LEPTOMYCIN B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER GENETICS; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; HUMAN; LEUKEMOGENESIS; MULTICENTER STUDY; ONCOLOGY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW;

EID: 0035210658 PISSN: 00937754 EISSN: None Source Type: Journal
DOI: 10.1053/sonc.2001.29184 Document Type: Review

Times cited : (55)

References (21)

1
- 0030766684
- Signal transduction pathways involved in BCR-ABL transformation
- (1997) Baillieres Clin Haematol , vol.10 , pp. 223-231
- Sawyers, C.L.¹

2
- 0029947186
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
- (1996) Nat Med , vol.2 , pp. 561-566
- Druker, B.J.¹ Tamura, S.² Buchdunger, E.³

3
- 0030853063
- The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
- (1997) Blood , vol.90 , pp. 3691-3698
- Deininger, M.W.N.¹ Goldman, J.M.² Lydon, N.³

4
- 0033585504
- In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
- (1999) J Natl Cancer Inst , vol.91 , pp. 163-168
- Le Coutre, P.¹ Mologni, L.² Cleris, L.³

5
- 85112352613
- In vitro effects of ST1571-containing drug combinations on growth of Phpositive myelogenous leukemia-derived cells
- abstr
- (2000) Blood , vol.96
- Scappini, B.¹ Onida, F.² Kantarjian, H.³

6
- 0035810147
- Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
- (2001) N Engl J Med , vol.344 , pp. 1031-1037
- Druker, B.J.¹ Talpaz, M.² Resta, D.J.³

7
- 0035810142
- Activity of a specific inhibitor of BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
- (2001) N Engl J Med , vol.344 , pp. 1038-1042
- Druker, B.J.¹ Sawyers, C.L.² Kantarjian, H.³

8
- 0028813711
- Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
- The Leukemia Service
- (1995) Ann Intern Med , vol.122 , pp. 254-261
- Kantarjian, H.M.¹ Smith, T.L.² O'Brien, S.³

9
- 0006971641
- Gleevec (imatinib mesylate) Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ
- (2001)

10
- 0023841366
- Characteristics of accelerated disease in chronic myelogenous leukemia
- (1988) Cancer , vol.61 , pp. 1441-1446
- Kantarjian, H.M.¹ Dixon, D.² Keating, M.J.³

11
- 0031934179
- Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
- (1998) Hematol Oncol Clin North Am , vol.12 , pp. 31-80
- Kantarjian, H.M.¹ Giles, F.J.² O'Brien, S.M.³

12
- 23444462074
- Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
- (1994) N Engl J Med , vol.330 , pp. 820-825

13
- 0006988859
- Data on file. [Integrated Summary of Efficacy-Update (cut-off 31-Jan-01)]. Novartis Pharma AG, Basel, Switzerland

14
- 0028170517
- Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia
- (1994) Blood , vol.84 , pp. 4064-4077
- Hehlmann, R.¹ Heimpel, H.² Hasford, J.³

15
- 0029154919
- A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase
- (1995) Blood , vol.86 , pp. 906-916
- Ohnishi, K.¹ Ohno, R.² Tomonaga, M.³

16
- 0342541022
- Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia
- (1998) Blood , vol.92 , pp. 1541-1548

17
- 0032522945
- Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-2b for chronic myeloid leukemia
- (1998) Blood , vol.91 , pp. 2713-2721

18
- 0029041749
- Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response
- (1995) Lancet , vol.345 , pp. 1392-1397
- Allan, N.C.¹ Richards, S.M.² Shepherd, P.C.³

19
- 0345696854
- Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
- (1997) N Engl J Med , vol.337 , pp. 223-228
- Guilhot, F.¹ Chastang, C.² Michallet, M.³

20
- 0035800507
- Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
- (2001) Science , vol.293 , pp. 876-880
- Gorre, M.E.¹ Mohammed, M.² Ellwood, K.³

21
- 0035122485
- Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase
- (2001) Nat Med , vol.7 , pp. 228-234
- Vigneri, P.¹ Wang, J.Y.J.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.